Literature DB >> 3534718

[Comparative in vitro activity of a new macrolide RU 28965 and of erythromycin against Chlamydia trachomatis].

B Dutilh, B de Barbeyrac, C Lafferrière, C Bébéar.   

Abstract

Activity of a new macrolide, RU 28965, and erythromycin against 8 Chlamydia trachomatis strains isolated from the human genital tract was studied. Minimal inhibitory concentrations were determined using cycloheximide-treated McCoy cells. Giemsa and immunofluorescence staining with monoclonal antibodies were used to detect Chlamydial inclusions. Immunofluorescence proved more sensitive and easier to read. All the strains were highly susceptible to RU 28965 (MIC = 0.05 mg/l - 0.1 mg/l) and erythromycin (MIC = 0.02 mg/l - 0.2 mg/l).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534718

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

1.  Roxithromycin treatment of mouse chlamydial salpingitis and protective effect on fertility.

Authors:  J Zana; M Muffat-Joly; D Thomas; J Orfila; J Salat-Baroux; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 3.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.